Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avant Immunotherapeutics, Inc.
Avant reports loss of $0.04 per share
June 2nd, 2006
Avant Immunotherapeutics, Inc., (AVAN) reported a net loss of $3.0 million, or $0.04 per share, for the first quarter of 2006 compared to a net loss of $4.9 million, or $0.07 per share for the first quarter of 2005. The decrease in net loss between periods primarily reflects an increase in product development and licensing revenue and product royalty revenue offset partly by higher operating expense. At March 31, 2006, Avant reported cash and cash equivalents of $59.8 million. Una S. Ryan, PhD, Avant's president and CEO, said, "These financial results were consistent with our expectations and we are encouraged with the progress of our programs during...
Source: Medicine & Law Weekly (2006-06-02)
|
